Nifty
Sensex
:
:
14504.80
48544.06
194.00 (1.36%)
660.68 (1.38%)

Pharmaceuticals & Drugs - Veterinary

Rating :
67/99

BSE: 512529 | NSE: SEQUENT

245.15
12-Apr-2021
  • Open
  • High
  • Low
  • Previous Close
  •  263.00
  •  267.00
  •  243.80
  •  267.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1009003
  •  2558.98
  •  279.00
  •  69.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 6,090.06
  • 63.27
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,344.88
  • N/A
  • 7.73

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 53.86%
  • 6.92%
  • 19.28%
  • FII
  • DII
  • Others
  • 13.15%
  • 2.68%
  • 4.11%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.22
  • 13.54
  • 4.59

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.11
  • 24.60
  • 8.84

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 2.97
  • 15.48
  • -45.06

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 21.91
  • 30.73

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.53
  • 3.27
  • 3.36

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 57.94
  • 25.65
  • 16.61

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
358.21
316.42
13.21%
346.27
284.22
21.83%
310.26
278.02
11.60%
300.58
281.90
6.63%
Expenses
291.91
266.44
9.56%
289.88
247.06
17.33%
259.25
239.57
8.21%
255.85
242.91
5.33%
EBITDA
66.31
49.98
32.67%
56.39
37.16
51.75%
51.02
38.44
32.73%
44.74
39.00
14.72%
EBIDTM
18.51%
15.80%
16.29%
13.07%
16.44%
13.83%
14.01%
13.83%
Other Income
2.81
0.98
186.73%
2.64
5.97
-55.78%
1.55
1.31
18.32%
1.83
2.43
-24.69%
Interest
6.20
9.60
-35.42%
7.36
7.84
-6.12%
7.65
8.95
-14.53%
9.33
8.90
4.83%
Depreciation
11.58
13.05
-11.26%
13.30
12.46
6.74%
13.03
12.01
8.49%
13.09
10.92
19.87%
PBT
51.33
28.31
81.31%
29.32
22.83
28.43%
31.89
18.80
69.63%
24.14
21.60
11.76%
Tax
11.64
4.25
173.88%
7.96
-1.64
-
7.42
3.50
112.00%
5.91
0.28
2,010.71%
PAT
39.69
24.06
64.96%
21.36
24.47
-12.71%
24.47
15.30
59.93%
18.23
21.32
-14.49%
PATM
11.08%
7.60%
6.17%
8.61%
7.89%
5.50%
7.11%
7.56%
EPS
1.50
0.82
82.93%
0.86
0.86
0.00%
0.84
0.46
82.61%
28.29
0.69
4,000.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
1,315.32
1,179.24
1,039.31
1,030.59
683.57
624.98
465.36
455.46
326.86
345.81
311.89
Net Sales Growth
13.33%
13.46%
0.85%
50.77%
9.37%
34.30%
2.17%
39.34%
-5.48%
10.88%
 
Cost Of Goods Sold
5,162.65
605.05
543.01
554.23
356.70
311.71
240.72
243.65
181.72
192.27
162.01
Gross Profit
-3,847.33
574.19
496.30
476.36
326.87
313.27
224.65
211.81
145.14
153.53
149.87
GP Margin
-292.50%
48.69%
47.75%
46.22%
47.82%
50.12%
48.27%
46.50%
44.40%
44.40%
48.05%
Total Expenditure
1,096.89
1,008.92
914.37
919.10
643.03
568.27
444.87
438.68
342.51
308.74
266.39
Power & Fuel Cost
-
24.73
23.06
14.66
12.77
26.51
23.32
22.06
23.53
20.21
16.75
% Of Sales
-
2.10%
2.22%
1.42%
1.87%
4.24%
5.01%
4.84%
7.20%
5.84%
5.37%
Employee Cost
-
165.06
145.95
132.07
106.22
88.62
62.39
48.12
41.47
29.40
29.82
% Of Sales
-
14.00%
14.04%
12.81%
15.54%
14.18%
13.41%
10.57%
12.69%
8.50%
9.56%
Manufacturing Exp.
-
83.24
77.73
59.07
57.63
72.14
54.31
52.30
41.42
27.88
33.72
% Of Sales
-
7.06%
7.48%
5.73%
8.43%
11.54%
11.67%
11.48%
12.67%
8.06%
10.81%
General & Admin Exp.
-
56.37
58.35
70.92
48.60
36.44
33.79
43.58
23.96
13.69
15.95
% Of Sales
-
4.78%
5.61%
6.88%
7.11%
5.83%
7.26%
9.57%
7.33%
3.96%
5.11%
Selling & Distn. Exp.
-
45.16
36.29
36.87
28.78
17.46
20.27
12.30
10.51
9.23
7.52
% Of Sales
-
3.83%
3.49%
3.58%
4.21%
2.79%
4.36%
2.70%
3.22%
2.67%
2.41%
Miscellaneous Exp.
-
29.32
29.98
51.29
32.34
15.40
10.07
16.66
19.91
16.05
7.52
% Of Sales
-
2.49%
2.88%
4.98%
4.73%
2.46%
2.16%
3.66%
6.09%
4.64%
0.20%
EBITDA
218.46
170.32
124.94
111.49
40.54
56.71
20.49
16.78
-15.65
37.07
45.50
EBITDA Margin
16.61%
14.44%
12.02%
10.82%
5.93%
9.07%
4.40%
3.68%
-4.79%
10.72%
14.59%
Other Income
8.83
10.09
8.67
17.20
11.08
14.30
9.96
3.84
4.96
10.48
6.69
Interest
30.54
35.71
32.80
39.70
28.34
38.56
44.37
39.04
33.45
29.99
23.80
Depreciation
51.00
50.62
41.92
53.30
40.07
46.22
32.94
32.60
28.61
22.98
20.69
PBT
136.68
94.08
58.88
35.70
-16.80
-13.77
-46.85
-51.00
-72.75
-5.41
7.69
Tax
32.93
12.03
2.01
13.46
-0.41
2.62
3.39
0.58
-8.06
-3.95
7.51
Tax Rate
24.09%
12.79%
3.41%
3.03%
2.44%
-19.03%
-40.50%
-0.53%
11.08%
73.01%
215.80%
PAT
103.75
69.91
48.66
421.57
-13.83
-18.47
-10.74
-110.49
-64.69
-1.40
-0.17
PAT before Minority Interest
97.64
82.05
56.88
430.83
-16.39
-16.39
-11.76
-110.49
-64.69
-1.46
-4.02
Minority Interest
-6.11
-12.14
-8.22
-9.26
2.56
-2.08
1.02
0.00
0.00
0.06
3.85
PAT Margin
7.89%
5.93%
4.68%
40.91%
-2.02%
-2.96%
-2.31%
-24.26%
-19.79%
-0.40%
-0.05%
PAT Growth
21.84%
43.67%
-88.46%
-
-
-
-
-
-
-
 
EPS
4.18
2.81
1.96
16.97
-0.56
-0.74
-0.43
-4.45
-2.60
-0.06
-0.01

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
742.76
706.69
647.58
976.79
945.71
91.27
56.73
95.00
122.53
123.06
Share Capital
49.67
49.37
48.75
48.75
47.65
30.48
26.74
23.44
21.34
21.23
Total Reserves
679.00
638.43
581.25
912.49
874.01
26.85
-0.37
59.68
101.19
101.82
Non-Current Liabilities
241.56
214.75
227.13
246.20
299.72
277.55
159.23
144.35
104.79
123.22
Secured Loans
107.97
126.94
85.14
141.76
197.50
249.97
150.52
137.32
80.19
90.73
Unsecured Loans
42.09
20.90
18.40
23.38
13.82
0.35
0.56
0.72
0.88
8.46
Long Term Provisions
13.16
30.50
28.54
34.76
28.66
25.70
8.03
6.09
15.49
11.74
Current Liabilities
479.57
440.41
430.93
663.55
290.37
406.09
405.28
345.41
329.56
199.21
Trade Payables
220.38
209.35
160.49
203.04
143.94
90.94
114.59
150.91
123.94
82.61
Other Current Liabilities
92.65
87.80
106.52
259.26
83.23
107.43
56.80
35.63
75.38
37.71
Short Term Borrowings
134.36
127.36
152.41
194.70
56.04
204.31
226.60
151.76
123.34
69.09
Short Term Provisions
32.19
15.90
11.51
6.54
7.17
3.42
7.29
7.12
6.89
9.80
Total Liabilities
1,508.63
1,402.10
1,342.62
1,903.76
1,538.02
921.84
625.82
589.34
562.37
446.25
Net Block
632.23
498.14
475.97
684.33
586.48
474.43
237.59
227.26
229.76
210.76
Gross Block
818.12
638.06
581.74
789.60
643.70
596.25
369.07
330.69
305.11
264.26
Accumulated Depreciation
185.89
139.91
105.77
105.27
57.22
121.82
131.48
103.43
75.35
53.50
Non Current Assets
794.52
795.99
804.61
1,176.02
1,047.48
612.00
359.87
358.31
351.94
282.23
Capital Work in Progress
13.42
22.61
18.04
32.55
23.52
39.06
43.04
88.71
64.07
19.53
Non Current Investment
131.29
179.65
221.73
363.97
360.58
58.04
0.04
1.64
0.04
0.05
Long Term Loans & Adv.
14.40
32.27
31.01
37.51
30.35
36.01
76.06
39.28
55.77
50.87
Other Non Current Assets
3.18
63.31
57.86
57.66
46.54
4.47
3.15
1.42
2.30
1.02
Current Assets
714.11
606.12
538.01
727.74
490.54
309.84
265.94
231.04
210.42
164.02
Current Investments
40.18
0.47
17.34
64.12
66.98
0.58
0.08
0.18
0.28
0.33
Inventories
219.42
200.10
158.57
160.81
135.08
94.36
101.40
85.62
68.24
65.55
Sundry Debtors
318.76
278.25
258.35
254.62
192.39
115.44
83.54
65.81
70.41
55.45
Cash & Bank
75.83
72.04
42.45
47.40
25.30
38.46
36.21
33.00
35.88
9.17
Other Current Assets
59.92
8.51
5.25
146.31
70.80
61.01
44.71
46.44
35.62
33.52
Short Term Loans & Adv.
44.41
46.75
56.05
54.48
46.69
41.86
37.47
36.48
28.84
31.25
Net Current Assets
234.54
165.71
107.08
64.19
200.17
-96.25
-139.34
-114.37
-119.13
-35.19
Total Assets
1,508.63
1,402.11
1,342.62
1,903.76
1,538.02
921.84
625.81
589.35
562.36
446.25

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
115.33
116.02
45.24
-7.19
-0.05
-23.55
-44.78
-3.82
21.48
49.63
PBT
94.08
58.88
445.79
-16.80
-13.77
-8.37
-109.91
-72.75
-5.41
3.49
Adjustment
91.41
84.47
-313.85
123.31
83.81
35.92
133.52
65.98
46.98
36.77
Changes in Working Capital
-58.30
-27.95
-77.87
-104.37
-71.46
-53.98
-67.45
2.48
-17.29
15.96
Cash after chg. in Working capital
127.18
115.40
54.06
2.14
-1.42
-26.44
-43.84
-4.28
24.27
56.22
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-11.85
0.62
-8.83
-9.33
1.37
2.89
-0.95
0.46
-2.79
-6.59
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-72.27
-67.69
7.17
-116.18
-315.83
-154.69
-79.95
-54.89
-66.78
-71.77
Net Fixed Assets
-29.66
-32.63
221.87
-49.63
97.97
38.51
-26.62
-28.82
-41.67
-80.90
Net Investments
30.56
-101.61
210.25
0.26
-713.97
-118.07
-10.37
-15.66
-25.20
31.50
Others
-73.17
66.55
-424.95
-66.81
300.17
-75.13
-42.96
-10.41
0.09
-22.37
Cash from Financing Activity
-42.75
-20.08
-56.96
147.44
308.69
179.41
145.54
34.70
61.94
16.51
Net Cash Inflow / Outflow
0.31
28.25
-4.55
24.07
-7.19
1.17
20.80
-24.02
16.63
-5.62
Opening Cash & Equivalents
67.79
39.54
44.10
20.03
21.85
22.96
3.45
27.37
9.17
14.07
Closing Cash & Equivalent
68.10
67.79
39.54
44.10
20.03
21.83
22.96
3.45
27.37
9.17

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
29.34
27.86
25.85
39.44
38.69
3.76
1.97
7.09
11.48
11.59
ROA
5.64%
4.14%
26.54%
-0.95%
-1.33%
-1.52%
-18.19%
-11.23%
-0.29%
-0.97%
ROE
11.58%
8.63%
54.15%
-1.74%
-3.35%
-28.10%
-201.83%
-62.91%
-1.19%
-3.42%
ROCE
12.33%
9.24%
41.28%
0.87%
2.72%
6.93%
-16.09%
-9.86%
6.98%
9.11%
Fixed Asset Turnover
1.65
1.74
1.51
0.96
1.03
1.01
1.36
1.08
1.26
1.31
Receivable days
90.45
92.53
90.49
118.40
87.75
74.80
57.30
72.70
64.08
63.08
Inventory Days
63.56
61.85
56.34
78.37
65.41
73.58
71.75
82.12
68.11
69.36
Payable days
80.87
75.36
77.04
104.11
77.28
87.31
115.68
149.32
123.09
94.20
Cash Conversion Cycle
73.14
79.02
69.78
92.66
75.87
61.07
13.36
5.51
9.10
38.25
Total Debt/Equity
0.45
0.47
0.48
0.43
0.34
8.26
15.86
3.74
2.19
1.54
Interest Cover
3.63
2.80
12.19
0.41
0.64
0.81
-1.82
-1.18
0.82
1.15

News Update:


  • SeQuent Scientific gets ‘Certificate of Suitability’ approval for Diclazuril API
    28th Jan 2021, 16:20 PM

    Diclazuril is an antiprotozoal drug and is a preferred drug of choice for treating coccidiosis in livestock due to zero-day withdrawal period

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.